Format

Send to

Choose Destination
Clin Pharmacol Ther. 2012 Mar;91(3):542-9. doi: 10.1038/clpt.2011.320. Epub 2012 Feb 8.

The role of physiologically based pharmacokinetic modeling in regulatory review.

Author information

1
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. ShiewMei.Huang@fda.hhs.gov

Abstract

During regulatory review of clinical pharmacology data in new drug applications and biologics license applications, questions are routinely asked about how intrinsic factors (e.g., organ dysfunction, age, and genetics) and extrinsic factors (e.g., drug-drug interactions) might influence dose-response and exposure-response and about the impact of these individual factors on the efficacy and safety of the candidate compound. Physiologically based pharmacokinetic (PBPK) modeling and simulation is one of the tools that can be used to address these critical questions.

PMID:
22318616
DOI:
10.1038/clpt.2011.320
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center